Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAVE-Stroke: Edoxaban 15mg vs 30mg in Elderly AF Patients
NCT06900725Phase 3Not yet recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of edoxaban in Atrial fibrillation (AFib), ischemic stroke and Transient Ischemic Attack (TIA), sponsored by National Taiwan University Hospital. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06900725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900725.